Stevanato Group S.p.A. (FRA:87N)

Market Cap	3.78B -20.8%
Revenue (ttm)	1.19B +7.5%
Net Income	139.84M +18.7%
EPS	0.51 +18.6%
Shares Out	n/a
PE Ratio	27.07
Forward PE	23.01
Dividend	0.05 (0.42%)
Ex-Dividend Date	Jun 5, 2025

Volume	n/a
Average Volume	0
Open	13.00
Previous Close	13.30
Day's Range	12.90 - 14.10
52-Week Range	11.30 - 23.60
Beta	n/a
RSI	64.76
Earnings Date	May 7, 2026

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injector...

• Industry: Commercial Physical and Biological Research
• Founded: 1949
• Employees: 6,010
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 87N

Financial Performance

In 2025, Stevanato Group's revenue was 1.19 billion, an increase of 7.45% compared to the previous year's 1.10 billion. Earnings were 139.84 million, an increase of 18.73%.